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Abstract
Matrix metalloproteinases regulate pathophysiological events by processing matrix proteins and secreted proteins.
Previously, we demonstrated that soluble heat shock protein B1 (HSPB1) is released primarily from endothelial cells (ECs)
and regulates angiogenesis via direct interaction with vascular endothelial growth factor (VEGF). Here we report that MMP9
can cleave HSPB1 and release anti-angiogenic fragments, which play a key role in tumorprogression. We mapped the
cleavage sites and explored their physiological relevance during these processing events. HSPB1 cleavage by MMP9
inhibited VEGF-induced ECs activation and the C-terminal HSPB1 fragment exhibited more interaction with VEGF than did
full-length HSPB1. HSPB1 cleavage occurs during B16F10 lung progression in wild-type mice. Also, intact HSPB1 was more
detected on tumor endothelium of MMP9 null mice than wild type mice. Finally, we confirmed that secretion of C-terminal
HSPB1 fragment was significantly inhibited lung and liver tumor progression of B16F10 melanoma cells and lung tumor
progression of CT26 colon carcinoma cells, compared to full-length HSPB1. These data suggest that in vivo MMP9-mediated
processing of HSPB1 acts to regulate VEGF-induced ECs activation for tumor progression, releasing anti-angiogenic HSPB1
fragments. Moreover, these findings potentially explain an anti-target effect for the failure of MMP inhibitors in clinical trials,
suggesting that MMP inhibitors may have pro-tumorigenic effects by reducing HSPB1 fragmentation.
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Introduction
Heat shock proteins (HSPs) were first identified as molecular
chaperones; recently, however, additional functions of HSPs in
physiological and pathological processes have been elucidated [1].
Small HSPs function in apoptosis inhibition, cellular protection,
and proteosomal degradation through direct binding of various
molecules [2,3]. HSPB1 (HSP27/25 in the human/mouse form)
and aB-crystallin, both members of a small HSP protein family,
share the conserved domain of a-crystallin. It has recently been
reported that the N-terminal domain serves as a platform for
modulation of HSPB1 assembly and dynamics and consequently
regulates their function [4].
Serum HSPB1 has been suggested as a prognostic marker of
tumor malignancy because HSPB1 serum levels are elevated in
cancer patients [5,6,7]. We have previously shown that overex-
pression of HSPB1 in cancer cells induces radio- and chemo-
resistance [8,9]. However, the role of HSPB1 in cancer remains
unclear. HSPB1 serine 82 phosphorylation by VEGF activation of
PKC-mediated PKD induces endothelial migration and tubulo-
genesis, indicating the potential importance of HSPB1 in VEGF-
dependent angiogenesis [10]. Recently, we reported that extra-
cellular HSPB1, secreted primarily from endothelial cells, main-
tains the angiogenic balance via direct binding with VEGF [11].
The matrix metalloproteinases (MMPs) have been associated
with multiple pathophysiological processes such as arthritis,
cancer, atherosclerosis, tissue ulcer and fibrosis. Moreover, the
roles of MMPs in cancer progression are thought to be more
complex than their degradative action on ECM components
[12,13]. Overexpression of some members of MMPs has been
correlated with the invasion, metastasis, and poor prognosis [14].
For examples, MMP2, membrane type-1 MMP (MT1-MMP),
and MMP9 are implicated in the invasion and metastasis in head
and neck squamous cell carcinoma [14]. Knockout of MMP-9
leads to reduced skin and pancreatic carcinogenesis and metastasis
showing delayed tumor vascularization [15]. Otherwise, knockout
of MMPs 23, 28, and 29 leads to enhanced tumorigenesis and
metastasis in some animal models of cancer [16].
In addition, MMP proteolysis regulates extracellular environ-
ment homeostasis, including mechanisms of host-resistance to
tumors [17]. Proteolytic processing of some ECM substrates, such
as laminin 5, releases new molecules with properties distinct from
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blocker, is a product of plasminogen formed by MMP2, MMP3,
MMP7, MMP9, and MMP12 cleavage in vitro. Endostatin, an
endogenous anti-angiogenic molecule, is generated from type
XVIII collagen by MMP3, MMP9, MMP12, MMP13, and
MMP20 processing in vitro [18]. Because inhibition of some MMPs
may have pro-tumorigenic effects (making them anti-targets), drug
selectivity must be considered to distinguish the actions of
proteases that contribute to tumor progression from those that
are crucial for host defense [16].
In the development of MMP inhibitors (MMPI) as anticancer
drugs, extensive phase III clinical trials in patients with advanced
cancer failed. Universally, the trials failed to increase survival [19].
Therefore, for successful cancer therapy, MMPI must be
developed to minimize adverse reactions as anti-targets.
In this study, we demonstrate that HSPB1 processing by MMP9
releases anti-angiogenic fragments of HSPB1 and this cleavage
acts to maintain the angiogenic balance in tumor progression.
Therefore, we suggest that MMP9-induced HSPB1 cleavage is an
anti-target effect of MMPI that must also be considered in MMP
target validation and MMPI drug development.
Materials and Methods
Cell Lines
HUVECs (human umbilical vein ECs) and HUVEC-Ls (human
lung microvascular ECs) were obtained from Lonza. All ECs were
used within nine passages. B6F10 melanoma and CT26 colon
carcinoma cells were a kind gift from Sam S. Yoon. Human
osteosarcoma cells (HOS) and COS-7 cells (monkey kidney
fibroblast cells) were purchased from ATCC.
Primary Tumor Model
k-ras
LSL-G12D/WT; p53
Flox/Flox mice, a gift from Sandra Ryeom,
have been described previously [20,21]. Soft tissue sarcomas were
generated via intramuscular injection of Adeno-CRE (Cell
Biolabs). Lung adenocarcinomas were generated via intranasal
administration of Adeno-CRE. In vivo tumor model.
All protocols involving mice were approved by the Institutional
Animal Care and Use Committee of the Korea Institute of
Radiological and Medical Sciences. To generate lung tumor, 56
10
5–1.0610
6 B16F10 cells or CT26 cells were injected intrasplen-
ically or into the tail vein of MMP9-null mutant mice or wild-type
mice (C57BL/6 background). MMP9-null mice were purchased
from the Jackson Laboratory. Six mice were used in each group.
Lungs and livers were harvested two weeks after adenovirus
treatment, weighed, and fixed in formalin.
Cleavage Assays
Recombinant HSPB1 (rHSPB1) protein (2 mg; Stressgene) and
wild-type or mutant HSPB1 proteins were purified using an anti-
Flag M2 affinity gel. Purified proteins were then incubated for 5,
10, or 30 min at 37uC with MMPs (50 ng/ml) in a buffer
containing 50 mM Tris (pH 7.4), 10 mM CaCl2, and 80 mM
NaCl in a maximum volume of 60 mL. The reaction was
terminated by addition of Laemmli buffer and resolved on a
10% gradient SDS-PAGE gel.
Enzyme-Linked Immunosorbent Assay (ELISA)
Ninety-six well plates were coated overnight with Flag protein
or N-terminal HSPB1 protein at 4uC. Serum was incubated for
1 hr at room temperature and then washed. The Myc antibody or
C-terminal HSPB1 antibody were used as the primary antibodies.
For detection of intact HSPB1 in mouse serum, the appropriate
secondary antibodies were used. The assay was performed in
accordance with the manufacturer’s instructions.
VEGF-Binding Assay
VEGF 165 was added to 96-well plates. The plates were
incubated with 100 mL/well of serial dilutions of Flag-tagged
HSPB1 wild type or C-terminal HSPB1 proteins in PBS plus 1%
BSA at 37uC for 2 hours. The remaining proteins on VEGF were
detected with an anti-flag monoclonal antibody (1:1000, Sigma)
using ELISA.
Mass Spectrometry and Liquid Chromatography Mass
Spectrometry
HSPB1 digested with MMP9 was separated by 15% SDS-
PAGE. Bands of interest were excised, digested with trypsin, and
analyzed by matrix-assisted laser desorption/ionization-time of
flight mass spectrometry (MALDI-TOF MS) and liquid chroma-
tography-mass spectrometry (LC-MS) peptide mapping. Also, the
intact molecular weight was determined using MALDI-TOF MS
and LC-MS. MALDI-TOF MS and LC-MS peptide mapping
were analyzed by PROTEINWORKS Co. Ltd.
Vector Constructs
The PPTLS control vector for secretion was made by insertion
of a synthesized signal sequence (PPTLS) into the pcDNA3.1/
myc-His A vector (Invitrogen) using BamHI and EcoRI sites [22].
Human HSPB1 or its deletion mutants were cloned into the
expression vector p3xFLAG-myc-CMV
26 (Sigma). Flag-tagged
HSPB1 constructs were subcloned into the PPTLS control vector
using EcoRI and XbaI sites. Lentiviral constructs for short hairpin
RNAs (shRNAs) to silence human MMP9 and control lentiviral
constructs were purchased from Santa Cruz Biotechnology.
Purification of Recombinant HSPB1 Protein
To obtain recombinant HSPB1 and HSPB1 deletion mutant
proteins, COS-7 cells were stably transfected with HSPB1 and
HSPB1 deletion mutant constructs with the secretory signal
sequence. For high-yield recombinant protein production, the BD
CELLine 1000 system (BD Biosciences) was used, in accordance
with the manufacturer’s instructions. The recombinant proteins
were purified at 4uC by batch absorption using an anti-Flag M2
affinity gel (Sigma), again according to the manufacturer’s
instructions.
Immunoprecipitation and Immunoblotting
Recombinant Human VEGF-A165 (100 ng/mL; R&D Systems)
was incubated for 6 h at 4uC with Flag-tagged HSPB1 (1 ug/mL)
or HSPB1 fragment protein (1 ug/mL) in binding buffer
containing 10 mM HEPES, 150 mM NaCl, 20 mug/mL BSA,
and heparin (10 units). Flag antibodies with protein A-Sepharose
(80 uL; Sigma) were incubated for 4 h at 4uC. The immune
complexes were washed and analyzed by SDS-PAGE. Immuno-
blotting was performed using the Flag (Sigma) and VEGF (R&D
Systems) antibodies.
Immunofluorescence
Mice were euthanized and tissues were harvested and fixed in
formalin for the preparation of paraffin sections. Paraffin-
embedded tissue sections were deparaffinized in xylene, 95, 90,
and 70% ethanol, followed by phosphate buffered saline (PBS).
Epitopes were unmasked with 20 mg/mL proteinase K in PBS
with 0.1% Triton X-100. Sections were co-immunostained
overnight at 4uC with the CD31 mAb (1:100; Santa Cruz) and
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1 hr at room temperature with donkey anti-mouse Alexa 488- or
anti-goat Alexa594-conjugated secondary antibodies (1:500; Mo-
lecular Probes). The HSPB1 epitope for detecting the N-terminus
(Abcam, ab5579) corresponds to amino acids 10–21 and the
epitope for the C-terminus (Abcam, ab26942) corresponds to
amino acids 145–205. Cell nuclei were labeled with Hoechst dye
(1 ug/mL). Images were obtained with a Zeiss microscope.
Microvessel density was quantified after CD31 immunostaining
of five sections per tissue and five mice per cohort, as described
previously. Additional immunohistochemical analyses of HSPB1
and CD31 were performed as described previously [23]. Images
were obtained with a Zeiss microscope.
Tumor-derived EC Isolations
Tumor-derived EC isolations were performed according to
protocols described previously [11]. Tumor cells were grown in
Dulbecco’s modified Eagle medium (DMEM).
In vitro Endothelial Cell Assays
EC proliferation was assessed by MTT (3-(4, 5-dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide) assay, as described previ-
ously [11]. Recombinant human VEGF165 (30 ng/mL; R&D
Systems) and purified HSPB1 wild-type or mutant proteins (1 ug/
mL) were added where indicated.
Tumor-transendothelial Cell Migration Assay
Transendothelial cell migration assays were performed using an
assay kit (CytoSelect
TM Tumor Transendothelial Migration Assay
Kit; Cell Biolabs). HUVECs were plated onto 8-mm pore size
inserts in 24-well plates and allowed to form a confluent
monolayer on the membrane for 72 hrs. A confluent monolayer
was checked by immunofluorescence-staining ECs with anti-CD31
antibody. After HOS cells were marked with CytoTracker, they
were plated onto the endothelial cell monolayer in the upper
inserts via bottom inserts with or without recombinant HSPB1
protein (1 ug/mL; Stressgene) or neutralizing HSPB1 antibodies
(1 ug/mL; Stressgene). The tumor cells were allowed to transmi-
grate through the endothelium and membrane for 16 hrs. Non-
migratory cells were removed and migratory cells were lysed.
Fluorescence was determined with a fluorescence plate reader at
480 nm/520 nm.
Statistical Analyses
Student’s t-test and an analysis of variance (ANOVA) were used
to determine statistically significant differences between the
experimental groups. Statistical analyses were performed using
GraphPad Prism ver. 5.0 (GraphPad Software, Inc.). The band
intensities of all immunoblots were quantified by volume
densitometry using the Quantity-One software of the Bio-Rad
imaging system.
Results
Soluble HSPB1 is Secreted by Tumor Endothelial Cells
HSPB1 is elevated in the serum of patients with many types of
cancer, although its exact role in tumorigenesis and metastasis has
yet to be determined [24,25,26]. Recently, we reported that
soluble HSPB1 is released primarily from endothelial cells (ECs)
[11]. To investigate the effect of soluble HSPB1 on tumor
progression, we performed tumor cell transendothelial migration
assays. Exogenous administration of HSPB1 inhibited the migra-
tion of HOS tumor cells through HUVECs, while HSPB1-
neutralizing antibodies that trapped soluble HSPB1 increased
tumor cell transendothelial migration (Figure S1A and B in File
S1).
As previously reported [11], we determined that HSPB1 is
highly expressed and secreted in tumor vascular ECs derived from
primary sarcoma and lung adenocarcinoma mouse models (K-
ras
LSL-G12D/WT; p53
Flox/Flox) compared to tumor cells (Figure 1A,
B and Figure S2 in File S1). Interestingly, cleavage of HSPB1 was
detected only in conditioned media from tumor vascular ECs, but
not from tumor cells (Figure 1A). To confirm the cleavage of
HSPB1 in vivo, we performed ELISA assays using N-terminal
(amino acids 10–21) and C-terminal (amino acids 158–205)
HSPB1 antibodies. The cleavage of HSPB1 was higher in the
serum of K-ras
LSL-G12D/WT; p53Flox
/Flox mice bearing soft tissue
sarcomas and lung adenocarcinomas than in that of normal mice
(Figure 1C). These results suggest that secretion and fragmentation
of HSPB1 occurred primarily in tumor vascular ECs, not tumor
cancer cells, may be related to tumor development.
HSPB1 is Cleaved by MMPs
MMPs can cleave a variety of secreted and cell surface
molecules, which regulate EC activation in pathophysiological
conditions [27,28,29]. To test the hypothesis that HSPB1 is a
substrate of MMPs, we added BB94 (an MMP inhibitor,
batimastat) to HUVECs. BB94 significantly reduced HSPB1
fragment levels in HUVEC conditioned media, indicating that
HSPB1 can be cleaved by MMPs (Figure 2A). In in vitro cleavage
assays, HSPB1 was cleaved by MMP2, 3 and 9, but not by
ADAMTS1, whereas HSP70 was not cleaved by MMP9
(Figure 2B, C and Figure S3 in File S1). To characterize HSPB1
fragment, we examined HSPB1 rocessing by MMP9, because
MMP9 cleaved HSPB1 more clearly than MMP2 and 3 (Figure 2A
and Figure S3 in File S1). Both C- and N-terminal fragments were
detected after exposure to MMP9 in a time-dependent manner,
indicating that cleavage occurred in at least two stages (Figure 2C).
A fragment of a higher molecular mass (20 kDa) was produced
first, followed by a smaller 7 kDa fragment. Besides these two
major fragments, other cleavage patterns were suggested to be due
to post modification such as phosphorylation or glycosylation.
Interestingly, we detected the phosphorylation of fragmentation,
suggesting that the lower band of 20kDa is non-phosphorylated
form (Figure 2C and Figure S4 in File S1, white arrows). Also, it
has been reported that O-GlcNAcylation of HSPB1 was detectable
in metastatic cancer [30]. We are currently studying about post-
modification patterns of fragments.
Identification of HSPB1 Cleavage Sites
To identify HSPB1 cleavage sites, we performed MALDI-TOF
MS and LC MS (data not shown). Results suggested that the
7 kDa fragment corresponds to the N-terminus of HSPB1 and
contains the WDPF motif. Cleavage occurred between amino
acids 58 and 59 of HSPB1, and the higher-molecular fragment
contains the a-crystallin domain (Figure 3A). An antibody
detecting amino acids 10–21 of HSPB1 specifically recognized
the 7 kDa HSPB1 fragment (amino acids 1–58), whereas an
antibody detecting amino acids 158–205 recognized the 20 kDa
fragment (amino acids 59–205). To ensure that the fragments
generated in vitro cleavage assay are the same as the ones
identified in tissue culture, we used the blocking peptide against
amino acid 10–21 of HSPB1 as western blot blocking buffer. The
7 kDa fragments in vitro cleavage assay and tissue culture
disappeared in the presence of this blocking peptide, suggesting
that the fragments generated in vitro cleavage assay are the same
as the ones identified in tissue culture (Figure S5 in File S1). Taken
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a substrate of MMPs.
Characterization of the Soluble HSPB1 Fragments
To further explore the significance of soluble HSPB1 cleavage,
we generated secretory constructs that mimicked the MMP9-
induced HSPB1 fragments (amino acids 1–58 and 59–203) as well
as an MMP-resistant HSPB1 mutant (HSPB1D54–63; Figure 3B
top). Transfection of wild-type HSPB1 that contained a secretory
signal sequence (PPTLS) into COS-7 cells increased secretion of
HSPB1 into the conditioned media compared to wild-type HSPB1
with no secretory signal sequence (Figure 3B, bottom). An HSPB1
mutant consisting of a 10 amino acid deletion between residues 54
and 63 did not cleaved by MMP9, indicating an MMP9-resistant
form of HSPB1 (Figure 3C). MMP2 and 3 caused cleavage of this
mutant, indicating that amino acids 54–63 of HSPB1 are not
necessary for digestion by MMP2 and 3 (Figure 3D). Taken
together, our data suggest that amino acids 54–63 of HSPB1 are
accessible sites for digestion by MMP9.
HSPB1 C-terminal Fragment Bound more Specifically to
VEGF165
We have previously shown that soluble HSPB1 interacts directly
with VEGF165 and regulates angiogenesis [31]. Thus, we
investigated the binding of HSPB1 fragments to VEGF165. In vitro
binding assays showed that the C-terminal fragment of HSPB1
interacted more strongly with VEGF165 than did wild-type
HSPB1; the N-terminal fragment of HSPB1 did not interact with
VEGF165 (Figure 4A). As shown in Figure 4a, the in vitro of
VEGF165–binding activities of wild-type HSPB1 and the C-
terminal fragment of HSPB1 were measured by ELISA. At a
concentration range of 0.05 to 10 uM, absorbance at 405 nm
(OD405) in the C-terminal fragment of HSPB1 was higher than
that of HSPB1 wt, which indicates that more the C-terminal
fragment of HSPB1 bound to VEGF165 than HSPB1 wt
(Figure 4B). Using the binding curve, the dissociation constant
(Kd) value of HSPB1 wt (Kd=10.83 uM) or HSPB1 C-terminal
fragment (Kd=0.78 uM) binding to VEGF (0.5 ug) was calculat-
ed by Scatchard analysis (Figure 4C). Because a lower Kd
represents a higher affinity to VEGF165, HSPB1 C-terminal
fragment bound more specifically to VEGF.
The MMP9-induced HSPB1 C-terminal Fragment
Inhibited VEGF165-mediated VEGFR2 Phosphorylation
To determine the effect of MMP9-cleaved HSPB1 fragments on
the VEGF-VEGFR2 pathway, we knocked downMMP9 in
HUVECs using MMP9 shRNA lentiviral vector. Cleavage of
HSPB1 protein was significantly reduced in the conditioned media
Figure 1. Soluble HSPB1 is secreted by tumor endothelial cells. A Co-localization of HSBP1 and CD31 on tumor vessels in soft tissue sarcomas
and lung adenocarcinomas derived from Kras
LSL-G12D/WT; p53
Flox/Flox mice was detected by immunofluorescence. B Tumor cells and tumor endothelial
cells (ECs) were isolated from sarcomas and lung adenocarcinomas of Kras
LSL-G12D/WT; p53
Flox/Flox mice and cell lysates were analyzed by western blot.
Secreted HSPB1 was detected in conditioned media (C.M.) from these cells. arrows, full length HSPB1; open arrows, cleaved HSPB1 C Serum HSPB1
levels in Kras
LSL-G12D/WT; p53
Flox/Flox mice with or without tumors were measured by ELISA assays for detecting intact HSPB1 as described in Methods;
blue bars, anti-HSPB1 (10-21)+anti-HSPB1 (158-205) antibody. Red and green bars obtained from general ELISA assays using antibodies to the N- (10-
21) or C-termini (158-201) of HSPB1 (*P,0.05 and **P,0.01 vs intact HSPB1).
doi:10.1371/journal.pone.0085509.g001
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Consequently, in MMP9 knock-down cells, HSPB1 protein did
not inhibit phosphorylation of VEGFR2 by VEGF as compared to
an absence of HSPB1. Treatment with the C-terminal HSPB1
fragment was sufficient to inhibit VEGF phosphorylation
(Figure 5A). Although knockdown of only MM9 in HUVECs
appeared to inhibit VEGF-VEGFR2 phosphorylation, we con-
firmed that MMP9-cleaved HSPB1 enhanced more this inhibition
(Figure 5A). These patterns of HSPB1 fragmentation regulating
VEGF-VEGFR2 activity were similar to those in VEGF-induced
HUVEC proliferation (Figure 5B). In addition, in control cells
(PPTLS), overexpression of the C-terminal fragment of HSPB1
inhibited VEGF-VEGFR2 phosphorylation more than did wild-
type HSPB1, whereas the N-terminal fragment of HSPB1 did not.
In MMP9 knock-down cells, showing that control cells (PPTLS)
decreased VEGF-VEGFR2 phosphorylation compared to control
shRNA, wild-type HSPB1 did not inhibit VEGF-VEGFR2
phosphorylation compared to control cells (PPTLS), whereas
overexpression of C-terminal HSPB1 fragment showed such
inhibition (Figure 5C). These patterns were also observed in
VEGF-induced HUVEC proliferation (Figure 5D). Treatment
with C-terminal HSPB1 peptides inhibited VEGF-VEGFR2
activity, but N-terminal HSPB1 peptides (amino acids 10–21)
did not (Figure S6 in File S1). Taken together, these observations
suggest that the C-terminal fragment of HSPB1 released by
MMP9 exerts greater anti-angiogenic effects than full length
HSPB1.
Figure 2. HSPB1 is cleaved by MMPs. A HUVECs were treated for 24 hr with the MMP inhibitor BB94 (2 mM). Cleaved HSPB1 levels in conditioned
media (C.M.) were detected by western blot analysis using an HSPB1 antibody to amino acids 158-205. B Recombinant HSPB1 (2 mg/mL) was
incubated with ADAMTS1, MMP3, or MMP9 (50 ng/mL) for the indicated times. HSP70 (2 mg/mL) was incubated with MMP9 as a negative control.
HSPB1 cleavage was detected by immunoblot using the HSPB1 antibody to amino acids 158-205 as well as Coomassie staining. C Recombinant
HSPB1 (2 mg/mL) was incubated with MMP9 (50 ng/mL) for the times indicated and analyzed by western blot using antibodies against the C- (158-
205) and N-termini (10–21) of HSPB1.
doi:10.1371/journal.pone.0085509.g002
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It has been previously shown that MMP9 is upregulated in
tumor metastases [32,33] and HSPB1 secretion is increased in
tumorigenesis [31,34,35]. Thus, we investigated whether HSPB1
fragments could be detected in tumor metastases.
B16F10 melanomas, which do not express HSPB1 (Fig. S7A),
were injected into mice to generate lung metastases [23]. The
20 kDa fragment was observed in B16F10 lung tumor of wild-type
mice but not in MMP-null mice (Figure 6A). In immunofluores-
cence experiments, the N- and C-terminal fragments were
detected by HSPB1 antibodies recognizing amino acids 10–21
and 145–205, respectively. Co-staining with these antibodies
indicated non–cleaved full length HSPB1. In lung metastases from
wild-type mice, the N-terminal fragment of HSPB1 did not co-
stain with the C-terminal fragment, indicating that HSPB1
cleavage occurred significantly during lung progression
(Figure 6B, left). Moreover, the N-terminal HSPB1 fragment
was not visible in lung tumor tissues from wild-type, suggesting
that this fragment is likely degradable (Figure 6B left, Green). In
fact, in vitro cycloheximide chase experiments exhibited that the
degradation rate of the N-terminal HSPB1 fragment was
significantly faster than the C-terminal fragment and wild-type
HSPB1 (Figure S7B in File S1). In contrast, the N- and C-terminal
fragments of HSPB1 co-localized in lung tumor tissues from
MMP9-null mice, indicating that MMP9 mediates HSPB1
cleavage (Figure6B, right).
To confirm HSPB1 cleavage by MMP9 during tumor
progression, we generated B6F10 cell lines secreting wild-type
HSPB1 (consisting of a Flag-tagged N-terminus and a Myc-tagged
C-terminus). HSPB1 secretion was confirmed by western blot
analysis of conditioned media (Figure S7C in File S1). When
Figure 3. Characterization of HSPB1 intramolecular cleavage. A HSPB1 cleavage sites and a schematic representation of the resulting
fragments. The amino acid sequence of the HSPB1 fragment from a Coomassie blue stained gel was analyzed by MALDI-TOF and LC mass
spectrometry. The N-terminus or C-terminus HSPB1 fragments were detected by western blot analysis using N-terminal or C-terminal HSPB1
antibodies, respectively. B A schematic representation of the soluble vector for HSPB1. HSPB1 was tagged with an N-terminal 3XFlag and a C-terminal
Myc tag. For secretion of HSPB1, the preprotrypsin leader sequence (PPTLS) precedes the Flag sequence; these vectors contain an additional C-
terminal His tag. COS-7 cell lines stably transfected with control vector; PPTLS, secretory wild-type HSPB1; sHSPB1WT, N-terminal-deleted secretory
HSPB1 (59–203); sHSPB1 (59–203), or possible cleavage sequence-deleted secretory HSPB1 (D54–63); sHSPB1 (D54–63) were cultured in OPTI-MEM
media (1% FBS). Secretion of N-terminal Flag or C-terminal Myc tagged protein was detected by western blot analysis of the lysates and culture
supernatants (bottom). C Recombinant protein (wild-type or mutant HSPB1) was incubated for 30 min with MMP9 (2 mg/mL) and HSPB1 digestion
was examined by western blotting using the Flag antibody. D Recombinant protein of sHSPB1 (D54–63) was incubated for 30 min with MMP2, 3 and
9( 2mg/mL) and HSPB1 digestion was examined by western blotting using the Flag antibody.
doi:10.1371/journal.pone.0085509.g003
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immunoprecipitation of lung tissues with the Flag or Myc
antibodies pulled down full-length HSPB1 in MMP9-null samples,
but not in wild-type samples (Figure 6C, top). Immunoprecipita-
tion of lung tumor with the Myc antibody but not the Flag
antibody, pulled down a 20 kDa fragment corresponding to the C-
terminal wild-type HSPB1 fragment. This fragment was detected
to a lesser degree in the MMP-null sample (Figure 6C, bottom,
open arrows).
In addition, co-localization of Flag and Myc was more
significantly detected in a MMP9-null sample than in an wild-
type sample, indicating that HSPB1 cleavage reduced in MMP9-
null mice (Figure 6D). A small amount of C-terminal fragment
detected in MMP9 null mice is suggested due to other MMPs
processing such as MMP2 and 3, eventhough overall cleavage
pattern of HSBP1 by MMP2 and 3 is different from MMP9.
Moreover, HSPB1 wild-type or fragments secreted by B16F10
stable cell lines were detected significantly in tumor endothelia,
suggesting that soluble HSPB1 targets tumor vascular endothelium
and regulates tumor vasculature (Figure 6B, D). In addition, we
confirmed serum MMP9 levels of wild-type mice and MMP9-null
mice using ELISA assays (Figure S8A in File S1). MMP9 secretion
was increased in wild-type mice with lung tumor of B6F10 cell
lines compared to normal wild-type mice, while secreted MMP9
was not detected in the serum of MMP null mice. (Figure S8A in
File S1). Using ELISA assays, a double positive response of Flag or
myc antibody was significantly increased in MMP9-null mice
compared to wild-type mice, indicating reduced HSPB1 cleavage
in the MMP9 knockout strain (Figure S8B in File S1). Taken
together, our results suggest that HSPB1 is mainly cleaved by
MMP9 during tumor progression.
HSPB1 Fragments Inhibit Tumor Metastasis
Because the C-terminal HSPB1 fragment inhibits VEGF-
mediated angiogenesis, we hypothesized that HSPB1 cleavage
inhibits VEGF-regulated tumor progression in vivo. We examined
the effects of the C-terminal HSPB1 fragments on lung tumor
progression by generating C-terminal HSPB1-secreting B16F10
cell lines. Secretion of N-terminal HSPB1 fragments was
confirmed by western blot analysis of conditioned media
(Figure 7A). Additionally, B6F10 cell lines stably transfected with
secretory wild-type HSPB1 (s-WT) secreted more HSPB1 than did
cell lines with non-secretory wild-type HSPB1 (WT). Conditioned
media from B16 F10 cell lines transfected with secretory C-
Figure 4. HSPB1 C-terminal fragment bound more specifically to VEGF165.ARecombinant proteins (1 mg/mL) were incubated for 6 hr at
4uC with recombinant human VEGF (50 ng/mL). Immunoprecipitates using the Flag antibody were subjected to binding assays with VEGF165 and
western blotting using the Flag and VEGF antibodies. B The amount of HSPB1 WT or HSPB1 (59–203) bound to VEGF165 was measured by ELISA assay.
Data are presented as mean 6 SEM. **P ,0.01. C Kd value for binding of HSPB1 WT or HSPB1 (59–203) to VEGF165 were calculated by Scatchard
analysis. Slope of each line=2 1/Kd.
doi:10.1371/journal.pone.0085509.g004
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VEGF165-induced VEGFR2 phosphorylation and proliferation
of HUVECs than secretory wild-type HSPB1 (s-WT). These data
suggest that the secreted C-terminal HSPB1 fragment was also
biologically active in abrogating VEGF-mediated endothelial cell
activation (Figure 7B). The in vitro growth rates of the stably
transfected cell lines [s-WT, s-(59–203), and WT] were equivalent
to the growth rate of the control cell line (Figure S9 in File S1).
Secretory wild-type HSPB1 inhibited lung progression more than
did the non-secretory wild-type HSPB1. Moreover, the secretory
C-terminal HSPB1 fragment effectively inhibited growth of
B16F10 lung tumor, as compared to wild-type secretory HSPB1
(Figure S7C in File S1). These patterns were similar to those of the
microvessel density (MVD) of lung tumors. The secretory C-
terminal HSPB1 fragment significantly reduced intratumoral
MVD compared to secretory HSPB1 wild-type (Figure S7d in
File S1).
Collectively, HSPB1 cleavage by MMP9 is inhibited in B16F10
lung tumor progression and MVD. In addition, We also examined
the effect of HSPB1 fragment on liver tumor progression. Splenic
injection of B16F10 cell lines with the secretory C-terminal
HSPB1 effectively reduced liver tumor progression, compared to
secretory wild-type HSPB1 (Figure 7e). To confirm the effect of
HSPB1 fragment on other tumor cell lines, we made lung tumors
using CT26 colon carcinoma cells. Secretory C-terminal HSPB1
significantly inhibited CT26 lung tumor, while secretory wild-type
HSPB1 did not (Figure S10 in File S1). We suggest that the
inhibitory function of secretory wild-type HSPB1 may be depend
on tumor cell types, but C-terminal HSPB1 have the inhibitory
function consistently. Also, these data suggest that full-length
HSPB1 protein requires proteolytic degradation to release the C-
Figure 5. Effect of MMP9-induced HSPB1 cleavage on VEGF-mediated endothelial cell activation. A HUVECs infected with MMP9 shRNA
lentiviral and control vectors were pretreated for 30 min with rHSPB1 WT (1ug/ml) or rHSPB1 fragments (59–203; 1 mg/ml) and then incubated with
VEGF (30 ng/mL). After 10 min, cell lysates and conditioned media were subjected to western blotting using indicated antibodies. Bar graph shows 6
SEM of band intensities of P-VEGFR2 signals normalized to P-VEGFR2 signals of control for 3 independent experiments. B After 48 hr, proliferation of
HUVECs was analyzed by MTT assay. C Transendothelial migration of HOS cells in the presence of rHSPB1 WT (1ug/ml) or rHSPB1 fragments (59–203;
1 mg/ml). After HOS cells were marked with CytoTracker, they were allowed to attach and migrate to the HUVEC monolayer. Fluorescence graph of
migratory cells labeled with CytoTracker shows 6 SEM for three independent experiments (*P ,0.05 and **P ,0.01, upper graph). HUVECs infected
with MMP9 shRNA lentiviral and control vectors were subjected to tumor transendothelial migration assay in the presence of rHSPB1 WT (1ug/ml)
(bottom graph). D HUVECs infected with MMP9 shRNA lentiviral and control vectors were transfected with sHSPB1WT or sHSPB1 fragments (1–58,
59–203) and then activated with VEGF (30 ng/mL). After 10 min, cell lysates and conditioned media were subjected to western blotting. Bar graph
shows 6 SEM of band intensities of P-VEGFR2 signals normalized to P-VEGFR2 signals of control for 3 independent experiments. E After 48 hr,
proliferation of HUVECs was analyzed by MTT assay.
doi:10.1371/journal.pone.0085509.g005
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progression by regulating VEGF-induced ECs activation.
Discussion
We investigated the potential role of MMPs in the generation of
bioactive HSPB1. Here, we have identified HSPB1 as a novel
substrate of MMP9. Interestingly, we demonstrate that this
cleavage generates a more anti-angiogenic HSPB1 fragment
having endothelial inhibitory activity via interaction with VEGF.
Furthermore, HSPB1 cleavage by MMP9 occurred during tumor
progression and the anti-angiogenic HSPB1 fragment inhibited
intratumoral MVD and tumor growth. VEGF165 is known to be
cleaved by MMPs such as MMP9 and MMP3. Also, we found that
HSPB1 bound toVEGF121 lesser that VEGF165 (Figure S11 in File
S1). We are currently studying the structure of VEGF-HSPB1
complex, and this may explain the difference of binding activities.
Overall, these findings suggest that generation of anti-angiogenic
fragments from HSPB1 is important for understanding the
physiological function of MMP9.
Recent studies have shown that serum HSPB1 levels are related
to disease, suggesting it as a prognostic marker [36,37,38]. Serum
HSPB1 was decreased in atherosclerotic patients due to proteolytic
degradation in atherosclerotic plaques [39]. In addition, many
studies have shown that HSPB1 is upregulated in tumor tissues
[40,41,42]. Although increased blood serum HSPB1 levels have
been observed in cancer patients, only a small number of studies
have investigated the role of soluble HSPB1. Previously, we
showed that soluble HSPB1 is released primarily from endothelial
cells (ECs) and plays a key role in regulating the angiogenic
balance via direct interaction with VEGF [11]. Here, we suggest
that HSPB1 is primarily secreted from tumor endothelial cells, not
tumor cells and cleavage of soluble HSPB1 by MMP9 leads to
endogenous anti-angiogenic effects during tumor progression. The
C-terminal HSPB1 fragment by MMP9 binds more to VEGF165
than full-length HSPB1, which strongly inhibits VEGF165-induced
VEGFR2 activity on ECs. And subsequently, the reduced VEGF-
induced VEGFR2 activity may decrease the proliferation of ECs
and tumor cell transendothelial migration, causing decreased
tumor progression. To our knowledge, this is the first study to
demonstrate that HSPB1 cleavage by MMPs is associated with
activity against tumor progression.
Taken together, our data suggest that soluble HSPB1 inhibits
VEGF function and that cleavage of soluble HSPB1 is increased as
Figure 6. HSPB1 cleavage by MMP9 occurs during tumor progression. A B16F10 melanoma cell lines were injected into the tail vein of wild-
type and MMP9-null mice. 14 days later, lung tumor tissues were harvested. HSPB1 levels in the lung tissue samples were analyzed by western
blotting using the HSPB1 (158–205) antibody. B Immunofluorescence staining of the N-terminal and C-terminal HSPB1 fragments in normal and
B6F10 lung tissues using the HSPB1 (10–21) and (158–205) antibodies, respectively. C Lung tumor tissues were obtained via intravenous injection of
B6F10 cells secreting wild-type HSPB1 into wild-type or MMP9-null mice. Immunoprecipitates with control IgG, anti-Flag, and anti-Myc in lysates of
lung tumor tissues were subjected to western blot analysis using the indicated antibodies. D Immunofluorescence staining of the N-terminal and
C-terminal HSPB1 fragments in B6F10 lung tumor tissues, using the Flag and Myc antibodies, respectively.
doi:10.1371/journal.pone.0085509.g006
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defenses that inhibit tumor angiogenesis include the endogenous
angiogenesis inhibitors thrombospondin-1 and endostatin, which
counteract the effects of pro-angiogenic factors. This function
prevents the angiogenic switch in in situ carcinomas, which inhibits
the transition to an angiogenic phenotype [43,44,45,46]. In fact,
the matrix metalloproteinase ADAMTS1 mediates the release of
anti-angiogenic fragments from TSP1 and 2 [23]. MMPs produce
endostatin, an inhibitor of angiogenesis, from collagen XVIII [18].
In addition, we found that in PMA-treated U937 cells, HSPB1
cleavage occurred depending on MMP9 (Figure S12 in File S1),
suggesting that in tumor microenvironment, macrophages play a
role in MMP9-induced HSPB1 cleavage.
Our data demonstrate that the C-terminal HSPB1 fragment
inhibits VEGF-induced angiogenesis to a greater extent than does
full-length HSPB1. Additionally, the N-terminal fragment was
detected to a lesser degree in tumor metastatic tissues and blood
than the C-terminal fragment, suggesting that this fragment is
likely more degraded (Figure 6 and Figure S8b in File S1). Indeed,
in vitro cycloheximide chase experiments supported that the
degradation rate of the N-terminal HSPB1 fragment was
significantly faster than the C-terminal fragment and wild-type
HSPB1 (Figure S7b in File S1). Also, it was recently reported that
the N-terminus of HSPB1 is flexible and unfolded. Therefore, we
hypothesize that increased MMP9 activity during tumorprogres-
sion. induces HSPB1 cleavage, and subsequently, cleaved C-
terminal HSPB1 interacts with VEGF more than intact HSPB1
due to conformational changes. As shown inFigure 6, wild type
and C-terminal fragment of HSPB1 were mainly detected in
tumor endothelium during tumor progression, suggesting that
secreted and cleaved HSPB1 targeting tumor endothelium may
play an important role in the regulation of tumor angiogenesis. We
are currently studying the effects of HSPB1 glycosylation,
phosphorylation and dimerization on MMP9-induced HSPB1
cleavage during tumor progression. Taken together, our data
suggest that MMP9-induced HSPB1 cleavage acts to regulate the
activity of -tumor vascular ECs, releasing anti-angiogenic C-
terminal fragment against tumor progression.
In clinical trials of MMP inhibitors (MMPI) as anticancer drugs,
MMPIs failed to control advanced cancer. Some reports indicate
that this was due to the loss of the beneficial and protective actions
of MMP anti-targets that counterbalance the benefits of thera-
peutically blocking MMP targets in cancer [16,47,48,49]. It has
been suggested that the anti-angiogenic properties of MMPs may
Figure 7. Effect of HSPB1 cleavage on tumor progression. A B16F10 melanoma cell lines were stably transfected with PPTLS, sHSPB1WT,
sHSPB1 (59–203), and HSPB1WT. Cell lysates and conditioned media of two stable lines (1,2) were repectively subjected to western blotting (top).
B Effects of conditioned media of B16F10 stable cell lines on VEGF165-induced VEGFR2 activation and proliferation activity in HUVECs. C Mean
number of metastases at 14 days after intravenous injection of B6F10 stable cells into wild-type mice. The graph shows the mean 6 SEM from three
independent experiments of six mice per group f (*P ,0.05 and **P ,0.01 vs PPTLS). Right panel shows representative images. D Intratumoral
microvessel density (MVD) per high-powered field (h.p.f.) was quantified by CD31 immunofluorescence. (*P ,0.05 and **P ,0.01 vs PPTLS). E Mean
weight of liver with tumor at 14 days after intrasplenic injection of B6F10 stable cells into wild-type mice.
doi:10.1371/journal.pone.0085509.g007
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this study, we suggest that MMPIs destroy the biological processes
underlying the maintenance of an endogenous anti-angiogenic
balance, leading to the failed clinical trials. Finally, HSPB1
fragment levels in the blood of cancer patients may be a valuable
prognostic marker of MMPIs. Development of novel MMP
substrates may thus provide new strategies for successful cancer
therapies based on MMP inhibition.
Supporting Information
File S1 Contains the following: Figure S1. The effect of
soluble HSPB1 on tumor transendothelial migration A.
Transendothelial migration of HOS cells in the presence of
HSPB1 or an HSPB1-neutralizing antibody. HUVEC monolayers
were treated with PBS, control IgG, recombinant HSPB1 (1.5,
3 mg/mL), or HSPB1 neutralizing antibodies (1, 2 mg/mL). After
HOS cells were marked with CytoTracker, they were allowed to
attach and migrate to the HUVEC monolayer. Fluorescence
graph of migratory cells labeled with CytoTracker shows 6 SEM
for three independent experiments (*P,0.05 and **P,0.01). B.
Neutralizing activity of the HSP27 antibodies (Stressgene) was
assessed in C.M. from HUVECs. HSP27 antibodies (1ug/ml) were
incubated with 3 ml of C.M. for 6 hr and the immune complexes
precipitated with protein A-Sepharose (80uL; Sigma) and analyzed
by SDS-PAGE. Figure S2. Localization of HSPB1 in cancer
tissue. Immunohistochemical analyses of HSPB1 in soft tissue
sarcomas and lung adenocarcinomas derived from KrasLSL-
G12D/WT; p53Flox/Flox mice using antibody against HSPB1 C-
terminus (Santa cruz). (size bar, 20ul) Figure S3. HSPB1
cleavage by MMP2 or MMP3. Recombinant HSPB1 (2 mg/
mL) was incubated with MMP2 and 3 (50 ng/mL) for the
indicated times and analyzed by western blot using antibodies
against the C- (158–205) and N-termini (10–21) of HSPB1.
Figure S4. Phosphorylation patterns of HSPB1 frag-
ments. HUVECs cell lysates were incubated with MMP9 (50 ng/
mL) for 30 min and analyzed by western blot using antibodies
against HSPB1, phospho-HSPB1 (Ser82, Stressgene) and phos-
pho-HSPB1 (Ser72, Stressgene). Figure S5. Identification of
HSPB1 fragment by blocking peptide. HUVECs lysates
incubated with MMP9 (50 ng/mL) for 30 min and conditioned
media after 2 days incubation with Opti-MEM (0.1% FBS) were
subjected to western blot using mixed antibodies against HSPB1
(10–21)+HSPB1 (158–205) in the presence of blocking peptide
against amino acid 10–21 of HSPB1 or not. Figure S6. The
effect of N-terminal (10–21) or C-terminal HSPB1
peptide on VEGF-VEGFR2 activity. HUVECs were pre-
treated with N-terminal (10–21) or C-terminal HSPB1 peptide
(Abcam) for 30 min. After 5 min stimulation of HUVECs with
VEGF, the VEGFR2 phosphorylation status was detected by
western blotting. Figure S7. The degradation rate of the
HSPB1 fragments A. HSPB1 expression level in B16 F10
melanoma cells was determined by western blotting. B. COS-
7 cell lines expressing N-terminal Flag tagged secretory wild-type
HSPB1, N-terminal HSPB1 (1–58) or C-terminal HSPB1 (59–203)
were treated with cycloheximide (CHX, Sigma). After indicated
time points, Flag tagged protein in conditioned media was
detected by western blot analysis. C.Transfection efficacy of
secretary HSPB1 wild type in B16 F10 melanoma cells was
determined by western blotting. Figure S8. A. Serum MMP9
levels were analyzed by ELISA. Serum MMP9 of wild-type
and MMP9-null mice bearing B16F10 melanoma lung metastic
tumor was analyzed by ELISA. B. HSPB1 fragments in serum
were examined by ELISA for intact HSPB1 using Flag and Myc
antibodies as described in Methods; blue bars (Intact HSPB1),
anti-Flag (N-terminus)+anti-Myc (C-terminus) antibody. Red (N-
terminus fragment) and green (C-terminus fragment) bars
obtained from general ELISA assays using antibodies to the Flag
(N-terminus) or Myc (C-terminus) of HSPB1 (*P,0.05 and
**P,0.01 vs intact HSPB1). Figure S9. The growth rates of
stably transfected B16F10 cells were measured by MTT
assay. Figure S10. The effect of HSPB1 cleavage on lung
tumor progression of CT26 colon carcinoma cells A.
CT26 colon carcinoma cell lines were stably transfected with
PPTLS, sHSPB1WT, sHSPB1 (59–203). Cell lysates and condi-
tioned media were subjected to western blotting (top). B. Mean
weight of lung tumor at 14 days after intravenous injection of
CT26 stable cells into wild-type mice. The graph shows the mean
6 SEM from three independent experiments of six mice per group
f (**P,0.01 vs sWT). Right panel shows representative images.
Figure S11. HSPB1 bound slightly to VEGF121. Flag-
tagged recombinant HSPB1 Wild type proteins (1 mg/mL) were
incubated for 6 hr at 4uC with recombinant human VEGF121 or
VEGF165 (50 ng/mL). Immunoprecipitates using the Flag
antibodies were subjected to binding assays with VEGF121
orVEGF165 and western blotting using the Flag and VEGF
antibodies (R&D). Figure S12. MMP9- dependent HSPB1
cleavage in PMA-treated U937 cells PMA (20ng/ml, 24 hr) –
treated U937 cells were infected with MMP9 shRNA lentiviral
and control vectors, and then were subjected to HSPB1 cleavage
assay in vitro.
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